Latest News from Cleave Therapeutics
Unsprung traps keep PARP inihbitors effective (VCP/p97 is a key player in removal of trapped PARP1)
January 10, 2022
Killing Cancer Cells by Stressing Them Out
May 24, 2021
Cleave Therapeutics Licenses First-in-class VCP/p97 Inhibitor CB-5339 to CASI Pharmaceuticals for Greater China Region
March 08, 2021
Cleave Therapeutics Announces Preclinical Research Collaboration with Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)
September 09, 2020